TF investors in biotechnology stocks may be rattled by the nose-dive of the first heavyweight out of the earnings gate. , the $10 billion biotech exchange traded fund, has lost 0.8% in the past three trading sessions as 's reports this week, IBD spoke to Tushar Yadava, an iShares investment strategist, on whether the biotech sector has room to run: Tushar Yadava: Biotech investors entering for the first time are likely doing so in search of consistent growth - something the sector has delivered for a few years running.